Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

ObsErvational Study of the Practical Cinical UTility of the NuQ.® H3.1 Nucleosome Levels in Adult Patients With Sepsis to Facilitate Early Diagnosis and Prognostication. (EPICETUS)

A legfontosabb adatok

Ki végzi
Guy's and St Thomas' NHS Foundation Trust
Hol
Egyesült Királyság1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
34 fő vett részt
Kezdés
2023. dec. 18.
Befejezés
2025. júl. 4.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • NuQ H3.1 Nucleosome Assay
A regiszteradat frissítve
2026. június 4.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients must be at least 18 years of age to be included in the study
  • Patients must have been admitted to critical care emergently with signs and symptoms consistent with a possible diagnosis of sepsis: defined as one of these types of infections: respiratory system, renal and genito-urinary system, gastrointestinal and intra-abdominal system, central nervous system, musculoskeletal, sepsis or fever of unknown origin
  • A 'comparator' arm will be included of patients aged over 18yrs of age undergoing planned elective coronary artery bypass graft surgery with anticipated post-operative care in critical care unit

Ki nem vehet részt

  • The exclusion criteria are designed to remove confounding effects from concomitant conditions that may render the interpretation of the NuQ.® H3.1 assay impossible. These circumstances are few, but exclusions will include patients with limitations of care, including 'Do not attempt resuscitation' orders
  • Subjects with any other severe concurrent disease that, in the judgment of the Principal Investigator, would make the subject inappropriate for entry into this study
  • Patients in the 'comparator' arm who are undergoing cardiac surgery will be excluded if they have an active infection and specifically patients with a suspected or confirmed diagnosis of infective endocarditis
  • Any patient undergoing cardiac surgery with a condition that might influence their immune response will be excluded. These include but are not limited to uncontrolled HIV, AIDS, uncontrolled systemic lupus erythematosus, rheumatoid arthritis or mixed connective tissue disorder, previous cancer and previous treatment with chemotherapy or the recipient of a solid organ or bone marrow transplant
  • Any subject not meeting the criteria above
  • Patients who are re-admitted to intensive care unit within the same hospital admission
  • Patients with severe anaemia (as defined by a Hb<50g/dL) will be excluded

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a study to evaluate the diagnostic performance of the investigation NuQ. (R) H3.1 nucleosome assay as a diagnostic marker of sepsis in a population of patients admitted to critical care with signs suspicious of infection and consistent with the sepsis 3 definition. These patients will be compared to a group of adult surgical patients free from infection that are undergoing their first cardiac surgery.

A vizsgálat 2 csoportja

  • Sepsis

    Adult patients admitted to critical care with a presumed diagnosis of sepsis.

    Kezelés: NuQ H3.1 Nucleosome Assay

  • Cardiac surgery

    Adult cardiac surgery patients that are free from infection undergoing their first cardiac surgery.

    Kezelés: NuQ H3.1 Nucleosome Assay

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. június 4.